NDATOPICALCREAM
Approved
Nov 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
13
Data completeness
5/8 — Partial
IMPOYZ (clobetasol propionate) by R-Pharm US is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in corticosteroid responsive dermatoses is unknown. First approved in 2017.
Drug data last refreshed 12h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMPOYZ is a topical cream formulation of clobetasol propionate, a potent corticosteroid approved in 2017. It modulates signaling, immune function, inflammation, and protein regulation to treat corticosteroid-responsive dermatoses, though the precise mechanism in these conditions remains incompletely understood. The drug is used for inflammatory skin conditions where topical corticosteroid therapy is indicated.
Peak8.5 years to LOE
Product is at peak commercial maturity with 8.5 years of patent protection remaining; team sizing likely stable with focus on market maintenance and brand optimization.
Mechanism of Action
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in corticosteroid responsive dermatoses is unknown. The contribution to efficacy by individual components of the vehicle has not been established.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
Started Dec 2022
60 enrolled
Cataracts Infantile
Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata
Started Nov 2022
70 enrolled
Alopecia Areata
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Started Jun 2020
250 enrolled
Cataract
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Started Jun 2020
215 enrolled
Cataract
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
Started Jul 2013
28 enrolled
Plaque Psoriasis
Worked on IMPOYZ at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.